That is medical/insurance malpractice is a very tough case. The problem is that the expanded label approval occurred in mid-December, too late to update the formularies. So it is my understanding that the problem could correct itself by 2021. I could be wrong, but that is the biggest obstacle I currently see. I have taken a lot of notes though, and have not completely ruled it out.